Group 1 - The current policy direction for the domestic economy emphasizes the development of new productive forces, with a focus on emerging industries driven by policies and industry trends, such as domestic AI, deep-sea technology, and humanoid robots [1] - The international competitiveness of China's innovative drugs has significantly improved, with expectations of continued expansion in overseas market share, accelerating the overseas progress of innovative drugs, which will bring performance increments to Chinese pharmaceutical and biotechnology companies [1] - There is an increasing emphasis from the government and industry on "anti-involution," suggesting a focus on supply-side clearing driven by policies, breakthroughs in technological barriers, and the globalization layout of leading enterprises [1] Group 2 - The Science and Technology Innovation Board 100 ETF (588120) tracks the Science and Technology Innovation 100 Index (000698), which can have a daily fluctuation of up to 20%. This index is compiled by China Securities Index Co., Ltd., selecting 100 securities with medium market capitalization and good liquidity from the Science and Technology Innovation Board to reflect the overall performance of mid-cap securities in this market [1] - The constituent stocks of the index mainly cover new-generation information technology, biomedicine, and new materials, fully reflecting the growth and innovation characteristics of the Science and Technology Innovation Board [1] - Investors without stock accounts can consider the Guotai CSI Science and Technology Innovation Board 100 ETF Initiated Link C (019867) and Guotai CSI Science and Technology Innovation Board 100 ETF Initiated Link A (019866) [1]
20cm速递|科创板100ETF(588120)涨超1.0%,科技成长板块或受益流动性宽松
Sou Hu Cai Jing·2025-07-24 03:32